[Federal Register Volume 83, Number 183 (Thursday, September 20, 2018)]
[Notices]
[Pages 47633-47634]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-20423]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting Omics Assays to Investigate Molecular 
Regulation of Persistent HIV in

[[Page 47634]]

Individuals with Substance Use Disorder (R61/R33 Clinical Trial 
Optional).
    Date: October 3, 2018.
    Time: 12:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 
301-827-5842, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in 
the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 
Clinical Trial Optional).
    Date: October 12, 2018.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 
301-827-5842, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Coordinating Center to Support NIDA Rural Opioid HIV 
and Comorbidity Initiative (U24--Clinical Trial Not Allowed).
    Date: October 17, 2018.
    Time: 2:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20423 Filed 9-19-18; 8:45 am]
 BILLING CODE 4140-01-P